Cambrian Bio’s ATX-304 raised resting metabolic rate by up to 33%. Could obesity treatment move beyond appetite suppression?
Cambrian Bio will present new ATX-304 metabolic data at ObesityWeek 2026. See how AMPK activation could influence future obesity treatment.